InspireMD appoints Dr. Peter A. Soukas as Chief Medical Officer to advance carotid stenting and patient care innovations.
Quiver AI Summary
InspireMD, Inc. has appointed Dr. Peter A. Soukas as Chief Medical Officer to enhance its clinical and medical strategies as it prepares to launch its CGuard® Prime carotid stent system in the U.S. market. CEO Marvin Slosman expressed excitement about Dr. Soukas' expertise in carotid intervention and vascular diseases, which will be vital in advancing the company's mission to improve patient care and outcomes. Dr. Soukas, a respected figure in vascular medicine and an associate professor at Brown University, also maintains a clinical practice and has extensive experience as a principal investigator in multiple trials. He emphasized his commitment to fostering innovation and collaboration in the medical community to better serve patients. InspireMD aims to set industry standards with its MicroNet™ technology to achieve superior short- and long-term results in carotid stenting.
Potential Positives
- The appointment of Dr. Peter A. Soukas as Chief Medical Officer brings significant expertise in carotid intervention and vascular medicine, which is crucial for advancing the company's strategic goals.
- Dr. Soukas' background as a leading physician and researcher in vascular intervention adds credibility to InspireMD's mission and enhances its reputation in the medical community.
- His commitment to improving patient outcomes and advancing technology aligns with InspireMD's focus on innovative solutions like the CGuard® Prime stent system, potentially driving adoption and success in the U.S. market.
- The announcement indicates a robust commitment to building a strong clinical and medical leadership team, which is vital at this pivotal time for the company's product launch.
Potential Negatives
- Appointment of a new Chief Medical Officer may indicate previous leadership gaps or instability within the company's medical team.
- The press release does not provide specific information about the company's current financial status or sales figures for CGuard Prime, which could raise concerns about market acceptance and revenue generation.
- Dr. Soukas’ ongoing clinical practice while serving as CMO could lead to potential conflicts of interest or divided attention that might affect his role at InspireMD.
FAQ
Who has InspireMD appointed as Chief Medical Officer?
InspireMD has appointed Peter A. Soukas, M.D., as its Chief Medical Officer.
What is the focus of Dr. Soukas's expertise?
Dr. Soukas specializes in carotid intervention and peripheral vascular disease.
What product is InspireMD launching in the U.S. market?
InspireMD is launching the CGuard® Prime carotid stent system in the U.S. market.
What is the goal of InspireMD's CGuard Prime stent?
The goal is to provide best-in-class clinical outcomes for stroke prevention.
Where can investors find more information about InspireMD?
Investors can find more information on InspireMD's website at www.inspiremd.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NSPR Insider Trading Activity
$NSPR insiders have traded $NSPR stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NSPR stock by insiders over the last 6 months:
- GARY S ROUBIN purchased 41,322 shares for an estimated $99,999
- THOMAS J KESTER purchased 30,991 shares for an estimated $74,998
- PAUL STUKA purchased 20,661 shares for an estimated $49,999
- MARVIN SLOSMAN (CEO and President) purchased 10,330 shares for an estimated $24,998
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NSPR Hedge Fund Activity
We have seen 19 institutional investors add shares of $NSPR stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. added 940,831 shares (+99.5%) to their portfolio in Q2 2025, for an estimated $2,135,686
- HUNTLEIGH ADVISORS, INC. added 139,776 shares (+112.5%) to their portfolio in Q3 2025, for an estimated $336,860
- UBS GROUP AG added 124,638 shares (+inf%) to their portfolio in Q2 2025, for an estimated $282,928
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 72,565 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $164,722
- PARKMAN HEALTHCARE PARTNERS LLC added 63,889 shares (+5.5%) to their portfolio in Q2 2025, for an estimated $145,028
- AFFIANCE FINANCIAL, LLC added 61,248 shares (+32.4%) to their portfolio in Q3 2025, for an estimated $147,607
- IRONWOOD INVESTMENT MANAGEMENT LLC added 60,547 shares (+inf%) to their portfolio in Q2 2025, for an estimated $137,441
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NSPR Analyst Ratings
Wall Street analysts have issued reports on $NSPR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 05/12/2025
To track analyst ratings and price targets for $NSPR, check out Quiver Quantitative's $NSPR forecast page.
Full Release
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention.
“We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company,” said Marvin Slosman, Chief Executive Officer of InspireMD. “His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insights as we launch CGuard Prime into the U.S. market. Dr. Soukas has been a strong supporter of our work advancing our next generation CGuard Prime stent platform to transform patient care through best-in-class clinical outcomes. This transformational time for carotid intervention requires us to build a team to lead the field, and Dr. Soukas will be a tremendous contributor to our work ahead.”
Dr. Soukas brings significant experience and credentials in the field of vascular intervention to InspireMD. He serves as the Director of Vascular Medicine and the Peripheral Vascular Interventional Laboratory at The Miriam Hospital and is an Associate Professor of Medicine at The Warren Alpert Medical School of Brown University, where he also directs the Vascular and Endovascular Medicine Fellowship Program, which he founded. He is a Fellow of the American College of Cardiology, the Society of Vascular Medicine, the Society of Coronary Angiography and Interventions, and the American College of Physicians. In addition to his role at InspireMD, Dr. Soukas will be maintaining his clinical practice.
Dr. Soukas’ clinical expertise and leadership in the interventional community speaks volumes for his passion and commitment to improving patient outcomes and advancing technology and innovation. He has served as the site principal investigator on more than 24 trials in carotid stenting, the site principal investigator on more than 150 endovascular trials, is a highly sought-after speaker having delivered over 300 invited lectures, and is a prolific researcher, publishing dozens of peer-reviewed papers with deep relationships among other key opinion leaders who shape the field. He is board certified in cardiovascular disease, interventional cardiology, vascular medicine, and endovascular medicine, and is certified in noninvasive vascular lab interpretation.
“I'm honored to join InspireMD as Chief Medical Officer. As a physician, I've witnessed firsthand the devastating impact of stroke and the transformative difference that innovations like CGuard Prime can make for patients,” said Dr. Soukas. “Physicians depend on the partnership with industry to advance new innovation and the team at InspireMD is an incredible example of how this ecosystem works well. My commitment is to guide the company with oversight of clinical and medical topics that build on success to date while establishing greater awareness of this breakthrough stent platform. I'm excited to join this team while continuing to collaborate with our clinical partners to advance patient care.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit
www.inspiremd.com
.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
[email protected]
[email protected]
